HIV/AIDS Therapy

Analysis provides additional data for Prezista as part of HIV combination therapy

Published in Virus Weekly, September 12th, 2006

Additional safety and efficacy data for Prezista (darunavir) 300 mg tablets, an anti-HIV medication produced by Ortho Biotech Products, was presented at the 16th International AIDS Conference (AIDS 2006) in Toronto, Canada.

In an oral presentation, researchers reported data from patients who had reached 48 weeks of treatment in an ad hoc (unplanned) pooled analysis from the POWER 1 and POWER 2 studies.

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Prezista, a protease inhibitor formerly known as TMC114, in June 2006. Prezista, co-administered with 100 mg ritonavir (Prezista/rtv) and with other antiretroviral agents, is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Virus Weekly

Source: Virus Weekly (2006-09-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry